Net Loss per Share (Tables)

6 Months Ended

Jun. 30, 2025

Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders

Basic and diluted net loss per share attributable to common stockholders of the Company was calculated as follows (in thousands, except share and per share amounts):


	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Numerator:
Net loss attributable to common stockholders	$	(1,700	)	$	(17,862	)	$	(15,566	)	$	(30,531	)

Denominator:
Weighted average shares of common stock outstanding, basic and diluted		56,026,767			53,957,766			55,703,275			53,740,901

Net loss per share attributable to common stockholders, basic and diluted	$	(0.03	)	$	(0.33	)	$	(0.28	)	$	(0.57	)

Summary of Shares Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders

The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Options to purchase common stock		2,583,918		2,858,042		2,583,918		2,858,042
Unvested RSUs and PSUs		5,707,873		7,690,743		5,707,873		7,690,743
		8,291,791		10,548,785		8,291,791		10,548,785

Spero Therapeutics, Inc. 10-Q